# A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents

> **NCT02716233** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 2044 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** pegaspargase 1250 IU/m2 x 2
- **DRUG:** pegaspargase 2500 IU/m2 x 1

## Key facts

- **NCT ID:** NCT02716233
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-09-19
- **Primary completion:** 2022-04
- **Final completion:** 2027-03
- **Target enrollment:** 2044 (ACTUAL)
- **Last updated:** 2025-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716233, "A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02716233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*